{
    "2020-05-19": [
        [
            {
                "time": "2023-10-15",
                "original_text": "AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Enhertu",
                        "Breakthrough Therapy",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease",
                "features": {
                    "keywords": [
                        "GERAS-US Study",
                        "Societal Cost Burden",
                        "Alzheimer's Disease",
                        "Patients",
                        "Caregivers"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}